Launch of ESMO Virtual Plenaries Brings Rapid Access to Ground-breaking Cancer Research
17.2.2021 15:00:00 EET | Business Wire | Press release
ESMO, the leading organisation for medical oncology, has launched an important new service for rapidly disseminating research to accelerate the transition of results into practice for the benefit of cancer patients.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210217005495/en/
(Graphic: ESMO)
“In a world that runs fast, timeliness in bringing research advances to patients is critical. The lessons that we have learnt from the COVID-19 pandemic have taught us that we need to be creative in sharing research results, and we certainly don’t have to wait for the two or three times in the year when major oncology congresses take place,” says Solange Peters, ESMO President.
ESMO Virtual Plenaries will combine concise presentations of new data, insightful discussion and audience Q&A in live, easy-to-access, 60-minute online sessions at convenient times across international time zones. They will remain available on OncologyPRO, ESMO’s online resource portal, for subsequent viewing.
Every month, latest, original scientific data will be presented from randomised phase III oncology trials or phase II trials which demonstrate remarkable therapeutic benefit, scientific insight or progress in an area of unmet need.
“By timely presentation of clinical and scientific data, ESMO Virtual Plenaries will be complementary to and enhance the value of conventional scientific congresses, whilst adhering to the principles of peer review, analysis and audience interaction,” says George Pentheroudakis, ESMO Chief Medical Officer.
A maximum of two abstracts will be accepted for presentation each month (except September and November when ESMO hosts major congresses). Abstracts will be original data from international investigators, selected by appropriate independent ESMO specialists. After presentation and discussion in ESMO Virtual Plenaries, abstracts will be published in Annals of Oncology and will be eligible for encore presentation at the next ESMO Congress.
The first ESMO Virtual Plenary is on Friday, 19 February, 1300 CET
Efficacy of everolimus in patients with HR+/HER2- high risk early-stage breast cancer
The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology. ESMO Members or anyone with an already existing free ESMO Account will be able to log in and watch using their existing ESMO Account.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210217005495/en/
Contact information
European Society for Medical Oncology
Press Office
+41 91 973 19 01
media@esmo.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Completes Majority Acquisition in Italy-Based ISEM Packaging Group for AED 704 Million5.3.2026 23:02:00 EET | Press release
2PointZero Group PJSC (ADX: 2PointZero), a next-generation investment powerhouse focused on energy and consumer sectors, announced today that it has formally completed the transaction to acquire a majority position in ISEM, a leading European packaging group serving beauty, fashion, luxury, nutraceuticals and more, for AED 704 million through a combination of secondary and primary capital earmarked to accelerate organic and inorganic growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305800523/en/ 2PointZero Group completes majority acquisition in Italy-based ISEM Packaging Group for AED 704 million (Photo: AETOSWire) 2PointZero Group now holds 60.8% of ISEM, while Peninsula Capital and minority investors own the remaining 39.2%. This marks the start of a strategic partnership between 2PointZero and Peninsula. Together, the partners will reinforce ISEM’s leadership position with a focus on category and geographic expa
Xsolla Announces Reseller Program to Help Game Developers Unlock New Revenue Streams in Local Markets5.3.2026 19:00:00 EET | Press release
Xsolla, a leading global video game commerce company, today announced the Xsolla Reseller Program, a new product designed to help game developers scale and capture untapped revenue in local markets with no development needed. The program launches with a curated cohort of resellers and distributors in Southeast Asia and Latin America, with expansion into additional regions throughout 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305047070/en/ Graphic: Xsolla As game developers pursue global growth, they face a fundamental infrastructure challenge: billions of dollars in revenue remain untapped in emerging, cash-dependent economies, such as Southeast Asia, Latin America, the Middle East, and North Africa, where players purchase digital content through local distribution partners. In mature digital economies, developers seek to extend their reach and distribute digital inventory at scale through more partners and chan
Xsolla Agency Launches to Empower Creators Across Entertainment-Based Intellectual Property5.3.2026 17:23:00 EET | Press release
Xsolla, a global video game commerce company, today launched Xsolla Agency, a comprehensive service connecting game developers with premium entertainment-based intellectual property (IP). The integrated offering addresses critical challenges for game creators: access to world-class IP, global monetization capabilities, and the operational infrastructure needed to build sustainable businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305044119/en/ Graphic: Xsolla Xsolla Agency simplifies access to entertainment-based licenses through expert-led negotiations and industry relationships, offering affordable, monetization-focused deals structured for maximum ROI. Strategic IP partnerships increase discoverability, reduce user acquisition costs, and drive higher player spend through impactful LiveOps events and promotional campaigns. The service is backed by the same commerce infrastructure powering 1,500+ game developers
Onego Bio and Sigma Foods Enter Collaboration to Strengthen Egg Protein Innovation and Supply Resilience5.3.2026 17:00:00 EET | Press release
Onego Bio, a food ingredient company producing non-animal egg protein, and Sigma Foods ("SIGMA"), a leading multinational food company, have entered into a collaboration agreement to evaluate the functionality and commercial potential of Bioalbumen®, a non-animal egg protein made with using precision fermentation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305756400/en/ The partnership focuses on advancing ingredient innovation while addressing urgent challenges in today’s egg supply chain—including volatility, rising prices, and avian flu-related disruptions. Bioalbumen® offers a shelf-stable, animal-free alternative that delivers the same functional, nutritional, and sensory performance as traditional eggs, while helping safeguard supply continuity for food manufacturers. Additionally, this collaboration supports Sigma’s commitment to offering safe, nutritious, and high-quality food, while driving science-based inno
Vertex to Present New Data on JOURNAVX ® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures5.3.2026 17:00:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from a Phase 4 study of JOURNAVX® (suzetrigine), a prescription non-opioid pain signal inhibitor for the treatment of moderate-to-severe acute pain, in adults, that demonstrated effective pain management and enabled opioid-free recovery after a broad range of plastic surgical procedures. These data showed that the majority of patients (90.9%) in the study were opioid free through the end of treatment (up to 14 days), demonstrating the potential for JOURNAVX as a core element of opioid-free multimodal treatment for moderate-to-severe acute pain after aesthetic and reconstructive procedures. In contrast, the literature shows opioid-free rates of less than 10% with multimodal treatment without JOURNAVX. These data will be presented at the American Academy of Pain Medicine (AAPM) PainConnect 2026 meeting, March 5-8, 2026, in Salt Lake City, UT. This Phase 4 open-label, multicenter, single-arm study evaluated JOURNAVX w
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom